A Phase 1 Open-label Study Evaluating the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

Protocol: 
AAAR5312
Phase: 
I

A Phase 1 Open-label Study Evaluating the Safety, Tolerability,Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

Are you Eligible? (Inclusion Criteria)

1. Age ≥ 18 years at the time of signing the informed consent

2. Diagnosis of relapsed / refractory multiple myeloma.

3. Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
(2 - Ambulatory and capable of all self care but unable to carry out any
work activities. Up and about more than 50% of waking hours,
3 - Capable of only limited self care, confined to bed or chair more than
50% of waking hours,
4 - Completely disabled. Cannot carry on any self care. Totally confined to
bed or chair
5 - Dead)

4. Life expectancy of at least 3 months as per investigator`s judgment at
time of
screening

Specialty Area(s)

Trial Location

Herbert Irving Comprehensive Cancer Center
161 Fort Washington Ave.
Herbert Irving Pavilion
New York, NY 10032
United States